arrow
F

Francesco Passiglia

university of turin
H指数:36
被引数:4,412

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

CT-guided core needle biopsy of focal pulmonary lesions with coexisting interstitial lung abnormalities: a case-control study

CT引导下粗针穿刺活检伴间质性肺异常的肺局灶性病变: 病例对照研究

2026-01-300
OAAI
Real-world outcomes of second-line carboplatin plus pemetrexed after first-line osimertinib in EGFR-mutant advanced NSCLC: An international multicentre cohort study

EGFR突变晚期非小细胞肺癌患者在接受一线奥希替尼治疗后,接受卡铂联合培美曲塞二线治疗的实际疗效:一项国际多中心队列研究

2025-10-160
PRE
Prognostic and predictive implications of tumor suppressor gene alterations in non-small cell lung cancer

肿瘤抑制基因改变在非小细胞肺癌中的预后和预测意义

2025-10-060
OA
Advanced-stage ALK-positive non–small-cell lung cancer (NSCLC) patients: Real-world treatment patterns and outcomes from the Italian biomarker ATLAS database

晚期ALK阳性非小细胞肺癌(NSCLC)患者:来自意大利生物标志物ATLAS数据库的真实世界治疗模式与结果

2025-09-240
OAAI
Real-world outcomes of subsequent treatment strategies after durvalumab consolidation in stage III unresectable non-small cell lung cancer

III期不可切除非小细胞肺癌接受度鲁瓦姆布巩固治疗后后续治疗策略的真实世界结局

2025-06-010
OAAI
A prospective study on clinicians' attitudes and survival outcomes for patients with advanced NSCLC and poor performance status in the immunotherapy era: PICASO (GOIRC-04-2020)

一项关于免疫治疗时代下,临床医生对晚期非小细胞肺癌(NSCLC)及体力状态较差患者的态度与生存结局的前瞻性研究:PICASO(GOIRC-04-2020)。

2025-06-010
PRE
BRAF-mutant metastatic non-small cell lung cancer: Real-world data from the Italian biomarker ATLAS

BRAF突变型转移性非小细胞肺癌:来自意大利生物标志物ATLAS的真实世界数据

2024-09-011
PRE
Advanced ALK-positive non-small cell lung cancer (NSCLC) patients: Real-world treatment patterns and outcomes from the Italian biomarker ATLAS database

晚期ALK阳性非小细胞肺癌(NSCLC)患者:来自意大利生物标志物ATLAS数据库的真实世界治疗模式与结果

2024-09-010
PRE
MET exon 14 skipping mutations in non-small-cell lung cancer: real-world data from the Italian biomarker ATLAS database

非小细胞肺癌中的MET外显子14跳跃突变: 来自意大利生物标志物图谱数据库的真实数据

2024-09-010
OAAI
Extracellular vesicles miR-574-5p and miR-181a-5p as prognostic markers in NSCLC patients treated with nivolumab
2024-08-064
OAAI
Real-world outcomes of Italian patients with advanced non-squamous lung cancer treated with first-line pembrolizumab plus platinum-pemetrexed
2024-05-013
PRE
Short-Term Safety and Psychosocial Impact of the BNT162b2 mRNA COVID-19 Vaccine in Cancer Patients-An Italian Single-Center Experience
2023-01-090
OAAI